NASDAQ:AMAM • US6418711080
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NEW AMBRX BIOPHARMA INC (AMAM).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-01-16 | Baird | Downgrade | Outperform -> Neutral |
| 2024-01-10 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2024-01-09 | B. Riley Securities | Downgrade | Buy -> Neutral |
| 2023-11-29 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2023-11-20 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2023-11-15 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2023-11-14 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-10-23 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-10-23 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-09-25 | JMP Securities | Initiate | Market Outperform |
| 2023-09-18 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-09-13 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2023-09-12 | BTIG | Initiate | Buy |
| 2023-08-16 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-07-31 | RBC Capital | Initiate | Outperform |
| 2023-06-14 | B. Riley Securities | Initiate | Buy |
| 2023-06-02 | Oppenheimer | Initiate | Outperform |
| 2023-05-19 | Cantor Fitzgerald | Initiate | Overweight |
| 2023-04-05 | Baird | Maintains | Outperform |
| 2023-02-28 | Goldman Sachs | Maintains | Neutral |
| 2023-02-27 | Goldman Sachs | Maintains | Neutral |
| 2022-05-24 | Goldman Sachs | Maintains | Neutral |
| 2022-04-07 | Baird | Initiate | Outperform |
| 2022-02-28 | Goldman Sachs | Initiate | Neutral |
| 2021-07-13 | Cowen & Co. | Initiate | Outperform |
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 13.67M 32.59% | 7.46M -45.43% | 7.4M -0.80% | 2.497M -66.26% | 1.742M -30.24% | 5.135M 194.78% | 4.188M -18.44% | 29.663M 608.29% | 169.53M 471.52% | 334.87M 97.53% | 583.3M 74.19% | |
| EBITDA YoY % growth | -11.18M 45.25% | -62.27M -456.98% | -64.94M -4.29% | -70.731M -8.92% | -102.754M -45.27% | -75.893M 26.14% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -13.12M 41.61% | -64.42M -391.01% | -66.74M -3.60% | -80.348M -20.39% | -107.309M -33.55% | -114.651M -6.84% | -166.988M -45.65% | -168.817M -1.10% | -71.412M 57.70% | 45.269M 163.39% | 231.73M 411.90% | |
| Operating Margin | -95.98% | -863.54% | -901.89% | -3,217.79% | -6,160.09% | -2,232.74% | -3,987.31% | -569.12% | -42.12% | 13.52% | 39.73% | |
| EPS YoY % growth | N/A | N/A | N/A 36.03% | -0.77 -159.66% | -1.64 -113.40% | -0.78 52.35% | -0.97 -24.51% | -0.91 6.29% | 0.23 125.75% | 1.17 397.09% | 2.05 75.52% |
All data in USD
| Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.20 -95.00% | -0.19 | -0.19 45.43% | -0.21 42.87% | -0.22 -9.10% |
| Revenue Q2Q % growth | 835.258K -81.40% | 586.5K 2,832.50% | 586.5K -47.63% | 714K 1,328.00% | 714K -14.52% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -22.757M 17.22% | -21.933M -36.82% | -22.412M -16.91% | -24.422M 4.72% | -25.055M -10.10% |
All data in USD
14 analysts have analysed AMAM and the average price target is 29.07 USD. This implies a price increase of 3.82% is expected in the next year compared to the current price of 28.
NEW AMBRX BIOPHARMA INC (AMAM) will report earnings on 2024-03-26.
The consensus EPS estimate for the next earnings of NEW AMBRX BIOPHARMA INC (AMAM) is -0.2 USD and the consensus revenue estimate is 835.26K USD.
The consensus rating for NEW AMBRX BIOPHARMA INC (AMAM) is 75.7143 / 100 . This indicates that analysts generally have a positive outlook on the stock.